The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offe

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and

The U.S. ​Food and ‌Drug Administration ​has approved a ​first-of-its-kind drug from ⁠Takeda ​Pharma

Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Ja

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). Wh

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

SBLK, TAK and STBA made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 17, 2026.

TAK, VLO, PFX, SBLK and RELY have been added to the Zacks Rank #1 (Strong Buy) List on August 17, 20

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Vinod Khosla says AI is revolutionizing drug discovery, but drug testing needs to catch up with more

Takeda Pharmaceuticals (TAK) remains a hold, with shares near 52-week highs and uncertainty about a

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Takeda Pharmaceutical Co. Ltd.‘s

Takeda secured FDA approval for ORZEYFUL, a first-in-class oral orexin treatment for adults with nar

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S.

The FDA has approved Takeda Pharmaceuticals' oral drug for narcolepsy, the U.S. ​health regulator sa

ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safet

Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 Adj EPS guidance from $3.01 to $3.01 vs $1.57 ana

Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its ful

Takeda Pharmaceutical Co (NYSE:TAK) affirms FY2026 GAAP EPS guidance from $0.66 to $0.66. Affirms FY

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.48 per share which beat the analy

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the firs

Arrowstreet Capital Limited Partnership trimmed its position in shares of Takeda Pharmaceutical Co.

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Medicure (OTCMKTS:MCUJF - Get Free Report) a

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) is anticipated to post its Q1 2027 results befor

Japanese drugmaker ​Takeda Pharmaceutical's ‌dengue vaccine ​QDENGA ​has been approved ⁠by ​India's

Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) on Friday revealed encouraging secondary data from two piv

Takeda shares positive Phase 3 data for its oral psoriasis drug zasocitinib, showing high skin clear

New data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly se

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from

The developer of the world’s first end-to-end AI drug has projected a big leap in half-year earnings

Ministry of Health of the Republic of Indonesia Grants Plasma Fractionation License, Enabling Takeda

Takeda and Insilico Medicine launch a strategic AI drug discovery collaboration to identify next-gen

Silence Therapeutics ($SLN) stock surges as Cantor predicts key August Phase 2 data will be a major

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primar

Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh d

Takeda's psoriasis drug zasocitinib outperformed Bristol Myers Squibb's Sotyktu in a Phase 3

Takeda ((TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-bl

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with m

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions

Takeda eyes growth with FDA Priority Reviews for narcolepsy and PV drugs. Get the latest on TAK'

Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.28 per share which beat the analy

TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (

FDA clears Axsome's Auvelity for Alzheimer's agitation, backed by Phase 3 data, expanding it

Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2

Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipelin